PATIENT SPOTLIGHT

Not Bell’s Palsy

Fig 1 - a) Coronal CT, showing soft tissue mass in epitympanum, with tegmen erosion.  b) MRI, T1-weighted Gd + coronal image, showing non-enhancing epitympanic lesion, with secondary soft tissue opacification of mastoid cells

A 24 year old male patient presented with right facial palsy of 5 months duration. He had mild hearing loss in the right ear but denied any other symptoms.

CLINICAL SIGNS

The patient was treated by a neurologist for “Bell’s palsy” with high-dose prednisone but there was no improvement in facial nerve function. Exam showed an intact eardrum with soft tissue convexity in the attic, and a complete (grade 6/6) facial paralysis. CT revealed an erosive mass in the epitympanum (Fig. 1a), and MRI showed imaging characteristics consistent with epidermoid tumor (Fig. 1b). ENoG showed no response at maximal stimulation levels. EMG showed marked spontaneous activity in the facial muscles.

CLINICAL FINDINGS

At surgery, there was a keratin mass in the epitympanum (Fig. 2), with bony erosion of the tegmen and the tympanic segment of the fallopian canal, and a fistula of the lateral semicircular canal. The mass was removed via canal wall down mastoidectomy. The tegmen was repaired with cartilage. The facial nerve was explored and the bony fallopian canal was found to be dehiscent from the labyrinthine segment to the second genu (Fig.3). The nerve was anatomically intact, but compressed by the lesion. The nerve was surgically decompressed, removing the matrix from the exposed facial nerve sheath. Stimulation of the nerve proximal to the lesion produced a weak response at a threshold level of 0.8 mA. Post-operatively the patient did well. At 2 months, the facial nerve function recovered partially to a grade 4/6 level.

ENT and Allergy Associates, LLP

This patient was referred by a tri-state ENTA physician.

Our shared EHR facilitates a seamless referral process and transfer of medical records with the push of a button.

To refer a patient:

Call us direct at Physician Access Services (212) 241-4983

Thank you for your referrals.
DISCUSSION

Certain clinical features that are not characteristic of Bell's palsy deserve mention, because these should trigger a search for another etiology (see below). Palsy that is gradual in onset (greater than 72 hours) should raise the suspicion of a lesion causing extrinsic compression of the nerve, such as a cholesteatoma or neoplasm of the facial nerve, skull base, or parotid. Palsy that spares the brow and mimetic function is central in origin, and should raise the possibility of stroke; likewise facial paresis accompanied by somatic hemiparesis should suggest pathology in the motor cortex of the brain. Polycranial neuropathies could be associated with central nervous system pathology or skull base tumors (see above). Segmental facial palsy (i.e., sparing of certain branches) should raise the suspicion of a lesion distal to the stylomastoid foramen, such as a parotid tumor. Facial paralysis that fails to show any sign of recovery after 4 months is also suspicious, as all cases of Bell's palsy will show at least partial return of function within that time frame. Patients who have a history of a previous malignancy should be worked up for the possibility of metastatic disease. Although Bell's palsy is the most common cause of facial paralysis, this is a diagnosis of exclusion. The differential diagnosis is broad. Making a correct diagnosis is essential for proper treatment, and function can be regained in many cases.

Clinical Features not typical of Bell’s Palsy

- Gradual Onset
- Hyperkinesis
- Bilateral simultaneous palsy
- Associated neurological symptoms
- History of malignancy
- Slow progression beyond 2 weeks
- Segmental paralysis/paresis
- Presence of other cranial neuropathies
- Absence of recovery by 4 mos

By Eric Smouha, MD
Associate Professor
Department of Otolaryngology

Dr. Smouha is the Director of Otology and Neuro-otology at Mount Sinai. His clinical interests include hearing restoration, chronic ear disease, and lateral skull base tumors.